Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.57 |
| ▸ | TNKS | O95271 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8653073 | 0.99 | DHODH (0.56) | DHODHTNKSTNKS2PARP2PDE10A | |
| SCHEMBL1554240 | 0.90 | TNKS (0.51) | DHODHTNKSTNKS2PARP2HPSE | |
| SCHEMBL8653067 | 0.90 | TNKS (0.51) | DHODHTNKSTNKS2PARP2PDE10A | |
| SCHEMBL2460672 | 0.89 | DHODH (0.60) | DHODHTNKSTNKS2PARP2PDE10A | |
| SCHEMBL1554187 | 0.88 | DHODH (0.50) | DHODHTNKSTNKS2PARP2PDE10A | |
| Hydrochloric Acid SCHEMBL8570223 | 0.87 | DHODH (0.49) | DHODHTNKSTNKS2PARP2PDE10A | |
| SCHEMBL10566368 | 0.84 | TNKS (0.58) | DHODHTNKSTNKS2PARP2PARP1 | |
| SCHEMBL1581119 | 0.82 | PKN1 (0.51) | DHODHTNKSTNKS2PARP2HPSE | |
| SCHEMBL1579962 | 0.81 | PBK (0.47) | DHODHKDM4EALDH1A1HPGD | |
| SCHEMBL8571039 | 0.81 | TNKS (0.50) | DHODHTNKSTNKS2PARP2HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934307-B1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2011-04-27 | — | — | EP | disclosed |
| EP-2223920-A2 | Substituted azabicyclic compounds | Aventis Pharma Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7329675-B2 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20050038069-A1 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2005-02-17 | — | — | US | disclosed |
| US-6800645-B1 | INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| US-20020173527-A1 | Substituted azabicyclic compounds | ASTLES PETER CHARLES (GB) | 2002-11-21 | — | — | US | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173527-A1 | Substituted azabicyclic compounds | CBR1, NOX1, POR | DHODH 609/4885TNKS 1953/4885TNKS2 3454/4885 |
| US-20050038069-A1 | Substituted azabicyclic compounds | NR2C2, NR3C1, NR3C2 | DHODH 3446/4885TNKS 4799/4885TNKS2 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.